Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection

Journal of Medical Virology

Volumn 52, Issue 3, 1997, Pages 309-315

  Turbica, Isabelle ^a   Simon, François ^b   Besnier, Jean Marc ^a   Lejeune, Bernard ^c   Choutet, Patrick ^a   Goudeau, Alain ^a   Barin, Francis ^a  

^a CHU BRETONNEAU   (France)

^b BICHAT HOSPITAL   (France)

^c UFR des Sciences Pharmaceutiques   (France)

Author keywords

CD4 binding cite; Humoral immunity; V3

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN DOMAIN; SEROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD4; CHO CELLS; CRICETINAE; DISEASE PROGRESSION; EPITOPES, T-LYMPHOCYTE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PROGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030848360     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199707)52:3<309::AID-JMV12>3.0.CO;2-D     Document Type: Article

References (34)

1. Ariyoshi K, Harwood E, Chiensong-Popov R, Weber J (1992): Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet 340:1257-1258.
2. Back NKT, Thiriart C, Delers A, Ramautarsing C, Bruck C, Goudsmit J (1990): Association of antibodies blocking HIV-1 gp160-CD4 attachment with virus neutralising activity in human sera. Journal of Medical Virology 31:200-208.
3. Baillou A, Brand D, Denis F, M'Boup S, Chout R, Goudeau A, Barin F (1993): High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120. AIDS Research and Human Retroviruses 9:1209-1215.
4. Barin F, Lahbabi Y, Buzelay L, Lejeune B, Baillou-Beaufils A, Denis F, Mathiot C, M'Boup S, Vithayasai V, Dietrich U, Goudeau A (1996): Diversity of antibody binding to V3 peptides representing consensus sequences to HIV type 1 genotypes A to E: An approach for HIV type 1 serological subtyping. AIDS Research and Human Retroviruses 12:1279-1289.
5. Bolognesi DP (1995): Humoral immune responses to primary HIV isolates: Implications for vaccine development. In Girard M, Valette L (eds): "Retroviruses of Human AIDS and Related Animal Diseases." Lyon: Fondation Marcel Mérieux, pp 285-291.
6. Cavacini LA, Emes CL, Power J, Underdahl J, Goldstein R, Mayer K, Posner MR (1993): Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. Journal of Acquired Immune Deficiency Syndromes 6:1093-1102.
7. Chamat S, Nara P, Berquist L, Whalley A, Morrow W, Hohler H, Kang H (1992): Two major groups of anti-gp120 antibodies exist in HIV-infected individuals. Journal of Immunology 149:649-654.
8. Daar ES, Moudgil T, Meyer RD and Ho DD (1991): Transient high levels of viremia in patients with primary immunodeficiency virus type 1 infection. New England Journal of Medicine 324:961-964.
9. Gorny NK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S (1994): Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. Journal of Virology 68:8312-8320.
10. Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott, Higgins K, Dunlop N, Scandella JC, Eichberg JW, Steimer JE (1992): Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. Virology 66:172-182.
11. Ho DD, McKeating JA, Moudgil T, Daal ES, Sun N, Robinson JE (1991): Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralisation identified by a human monoclonal antibody. Journal of Virology 65:489-493.
12. Javaherian KA, Langlois J, McDanal C, Ross KL, Eckler LI, Jellis LC, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ (1989): Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proceedings of the National Academy Sciences of the United States of America 86:6768-6772.
13. Javaherian KA, Langlois J, LaRosa JG, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, Mattews TJ (1990): Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250:1590-1592.
14. Kang C, Nara P, Chamat S, Caralli V, Ryskamp T, Haigwood N, Newman R, Köler H (1991): Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proceedings of the National Academy Sciences of the United States of America 88: 6171-6175.
15. Koup RA, Safrit JT, Cao Y, Andrews CA, Mc Leod G, Borkowsky W, Farthig C, Ho DD (1994): Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Journal of Virology 68: 4650-4655.
16. McKeating JA, Thali M, Furman C, Karwowoska S, Gorny MK, Cordell J, Zolla-Pazner S, Sodroski J, Weiss RA (1992): Amino acids residues of the human immunodeficiency virus type 1 gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology 190:134-142.
17. Moore JP, Ho DD (1993): Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. Journal of Virology 67:863-875.
18. Moore JP, Cao Y, Ho DD, Koup RA (1994): Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. Journal of Virology 68:5142-5155.
19. Myers G, Korber B, Wain-Hobson S, Smith RF, Pavlakis GR (1992): "Human Retroviruses and AIDS." Los Alamos: Los Alamos National Laboratory.
20. Nara PL, Robey WG, Pyle SW, Hatch WC, Dunlop NM, Bess JW, Kellier JC, Arthur JO, Fischinger PJ (1988): Purified envelope glycoprotein from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. Journal of Virology 62:2622-2628.
21. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KM, Byrn RA (1991): An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. Journal of Immunology 146:4325-4332.
22. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R (1993): Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. Journal of Acquired Immune Deficiency Syndromes 6:7-14.
23. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, Matthews TJ (1988): Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope gp120. Proceedings of the National Academy Sciences of the United States of America 85:3198-3202.
24. Steimer KS, Scandella CJ, Skiles PV, Haigwood NL (1991): Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
25. Thali M, Olshevski U, Furman C, Gabuzda D, Posner M, Sodroski J (1991): Characterisation of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. Journal of Virology 65:6188-6193.
26. Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, Sodroski J (1992): Discontinuous, conserved neutralisation epitopes over-lapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. Journal of Virology 66:5635-5641.
27. Turbica I, Posner M, Bruck C, Barin F (1995): A simple enzyme-immunoassay for titration of antibodies to the CD4 binding site of HIV1 gp120. Journal of Clinical Microbiology 33:3319-3323.
28. Warraen RQ, Anderson SA, Nkya WM, Shao JF, Hendrix CW, Melcher GP, Redfield RR, Kennedy RC (1992): Examination of sera from human immunodeficiency virus type1(HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal determinant of HIV-1 gp120 and for in vitro neutralizing activity. Journal of Virology 66:5210-5215.
29. Warrier SV, Pinter A, Honnen WJ, Girard M, Muchmore E, Tilley SA (1994): A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a high potent, neutralizing chimpanzee monoclonal antibody. Journal of Virology 68:4636-4642.
30. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW and Hanson CV (1994): Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 7:211-219.
31. Wu Z, Kayman SC, Honnen W, Revesz K, Chen H, Vijh-Warrier S, Tilley A, McKeating J, Shotton C, Pinter A (1995): Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: Role of glycosylation in the correct folding of the V1/V2 domain. Journal of Virology 69:2271-2278.
32. Zwart G, Langedijk H, Van Der Hoeck, de Jong JJ, Wolfs TFW, Ramautarsing C, Bakker M, de Ronde A, Goudsmit J (1991): Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181:481-489.
33. Zwart G, Wolfs TFW, Valk M, Van der Hoek L, Kuiken CL, Goudsmit J (1992): Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1. AIDS Research and Human Retroviruses 8:1897-1908.
34. Zwart G, Back NT, Ramautarsing C, Valk M, Van der Hoek L, Goudsmit J (1994): Frequent and early HIV-1 MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Research and Human Retroviruses 10:245-251.